ARTV · Artiva Biotherapeutics, Inc.
$11.14
-0.56 (-4.79%)
At close · Aug 20
Market Cap
$544.64M
Shares
48.89M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.14
Open$11.50
Day$10.93–11.58
52W close$2.28–13.39
Avg vol 30d372K
Short int1.9M · 3.9% float · 5.1d
Short vol55%
Last earningsJun 8, 2026
DataJul 2024–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+60%
above
Price vs 50-day avg
+11%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
80%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+91%
trailing
YTD return
+160%
this year
Relative strength
+80%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+80% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$17.5M over 90 days · 0% sells
Short interest
Rising
3.93% of float · ▲ +11.5% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 2-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+41%
Y/Y
Free cash flow
$-79.3M
Balance sheet
$26.7M
net cash
Quant / Vol
risk profile
Volatility
184%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+60%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
80%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+80% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$17.5M over 90 days · 0% sells
Short interest
Rising
3.93% of float · ▲ +11.5% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $11 · 80%
Range high $13
vs 200-day avg +60%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARTV
this stock
Artiva Biotherapeutics, Inc.
|
$544.64M | +159.7% | -100.0% | — | 3.9% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARTV | -1.4% | +10.0% | +91.4% | +10.3% | +159.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.5% | +6.7% | +80.2% | +8.2% | +147.8% |
Key facts
CIK
1817241
CUSIP
04317A107
13F (30d)
74 filings
73 filers
Visit website
Investor relations